Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

The Acuvue Oasys Max 1-Day Multifocal marks the first and only daily disposable contact lens to be available for people with ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

At the moment, FP&A in pharma is going through a complex period of change. While new technologies are making it easier to collect and analyze data, external factors are making it much harder to ...

Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s ...

According to Sun Life, cancer is the most common and costly condition that its members face. Second opinions are important ...

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping ...

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...